Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
navitoclax (ABT 263)
i
Other names:
ABT 263, RG 7423, RG7433, RG 7433, RG7423, ABT-263
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(16)
News
Twitter
Trials
Company:
AbbVie
Drug class:
Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
Related drugs:
‹
venetoclax (383)
paclitaxel (163)
albumin-bound paclitaxel (57)
APG-2575 (7)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
A-1331852 (5)
venetoclax (383)
paclitaxel (163)
albumin-bound paclitaxel (57)
APG-2575 (7)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
A-1331852 (5)
›
Associations
(16)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
osimertinib + ABT 263
Sensitive
:
C2
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
osimertinib + ABT 263
Sensitive
:
C2
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
osimertinib + ABT 263
Sensitive
:
C2
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
osimertinib + ABT 263
Sensitive
:
C2
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
trametinib + ABT 263
Sensitive: D – Preclinical
trametinib + ABT 263
Sensitive
:
D
trametinib + ABT 263
Sensitive: D – Preclinical
trametinib + ABT 263
Sensitive
:
D
EGFR overexpression
Triple Negative Breast Cancer
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABBV-321
Sensitive: D – Preclinical
ABT 263 + ABBV-321
Sensitive
:
D
ABT 263 + ABBV-321
Sensitive: D – Preclinical
ABT 263 + ABBV-321
Sensitive
:
D
EGFR overexpression
Triple Negative Breast Cancer
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABT-414
Sensitive: D – Preclinical
ABT 263 + ABT-414
Sensitive
:
D
ABT 263 + ABT-414
Sensitive: D – Preclinical
ABT 263 + ABT-414
Sensitive
:
D
BCL2L2 overexpression
Diffuse Large B Cell Lymphoma
BCL2L2 overexpression
Diffuse Large B Cell Lymphoma
ABT 263
Resistant: D – Preclinical
ABT 263
Resistant
:
D
ABT 263
Resistant: D – Preclinical
ABT 263
Resistant
:
D
KRAS G12D
Lung Cancer
KRAS G12D
Lung Cancer
selumetinib + ABT 263
Sensitive: D – Preclinical
selumetinib + ABT 263
Sensitive
:
D
selumetinib + ABT 263
Sensitive: D – Preclinical
selumetinib + ABT 263
Sensitive
:
D
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
ABT 263 + AZD8055
Sensitive: D – Preclinical
ABT 263 + AZD8055
Sensitive
:
D
ABT 263 + AZD8055
Sensitive: D – Preclinical
ABT 263 + AZD8055
Sensitive
:
D
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
ABT 263 + AZD8055
Sensitive: D – Preclinical
ABT 263 + AZD8055
Sensitive
:
D
ABT 263 + AZD8055
Sensitive: D – Preclinical
ABT 263 + AZD8055
Sensitive
:
D
BCL2L1 overexpression
Pancreatic Cancer
BCL2L1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
CHEK1 overexpression
Pancreatic Cancer
CHEK1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
EGFR L8585R + EGFR T790M + RBM10 G840fs*7
Lung Cancer
EGFR L8585R + EGFR T790M + RBM10 G840fs*7
Lung Cancer
osimertinib + ABT 263
Sensitive: D – Preclinical
osimertinib + ABT 263
Sensitive
:
D
osimertinib + ABT 263
Sensitive: D – Preclinical
osimertinib + ABT 263
Sensitive
:
D
EGFR L858R + RBM10 Q255*
Lung Cancer
EGFR L858R + RBM10 Q255*
Lung Cancer
osimertinib + ABT 263
Sensitive: D – Preclinical
osimertinib + ABT 263
Sensitive
:
D
osimertinib + ABT 263
Sensitive: D – Preclinical
osimertinib + ABT 263
Sensitive
:
D
BCL2 overexpression
Lung Cancer
BCL2 overexpression
Lung Cancer
gefitinib + ABT 263
Sensitive: D – Preclinical
gefitinib + ABT 263
Sensitive
:
D
gefitinib + ABT 263
Sensitive: D – Preclinical
gefitinib + ABT 263
Sensitive
:
D
DKK3 overexpression
Glioblastoma
DKK3 overexpression
Glioblastoma
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login